Epizyme Inc.

1.47-0.0200-1.34%Vol 21.92M1Y Perf -72.81%
Aug 11th, 2022 16:00 DELAYED
BID1.47 ASK1.49
Open1.49 Previous Close1.49
Pre-Market- After-Market1.49
 - -  0.02 1.36%
Target Price
2.39 
Analyst Rating
Moderate Buy 2.50
Potential %
62.59 
Finscreener Ranking
     34.61
Insiders Trans % 3/6/12 mo.
-/-100/-80 
Value Ranking
+     35.15
Insiders Value % 3/6/12 mo.
-/-100/100 
Growth Ranking
     37.83
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
19.53 
Earnings Rating
Strong Sell
Market Cap247.50M 
Earnings Date
8th Aug 2022
Alpha0.01 Standard Deviation0.40
Beta-0.45 

Today's Price Range

1.471.50

52W Range

0.41105.83

5 Year PE Ratio Range

-5.20-5.50

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
-3.29%
1 Month
-1.34%
3 Months
173.85%
6 Months
-9.82%
1 Year
-72.81%
3 Years
-87.55%
5 Years
-88.78%
10 Years
-

TickerPriceChg.Chg.%
EPZM1.47-0.0200-1.34
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
73.50
-551.10
-537.50
-907.50
-
RevenueValueIndustryS&P 500US Markets
25.48M
0.15
8.09
29.76
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.36-0.2141.67
Q01 2022-0.35-0.39-11.43
Q04 2021-0.41-0.49-19.51
Q03 2021-0.45-0.64-42.22
Q02 2021-0.60-0.63-5.00
Q01 2021-0.56-0.69-23.21
Q04 2020-0.59-0.65-10.17
Q03 2020-0.61-0.559.84
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.36-33.33Negative
9/2022 QR-0.32-18.52Negative
12/2022 FY-1.38-18.97Negative
12/2023 FY-1.21-7.08Negative
Next Report Date-
Estimated EPS Next Report-0.36
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume21.92M
Shares Outstanding168.36K
Shares Float100.91M
Trades Count11.15K
Dollar Volume32.29M
Avg. Volume2.78M
Avg. Weekly Volume2.63M
Avg. Monthly Volume2.21M
Avg. Quarterly Volume3.50M

Epizyme Inc. (NASDAQ: EPZM) stock closed at 1.47 per share at the end of the most recent trading day (a -1.34% change compared to the prior day closing price) with a volume of 21.92M shares and market capitalization of 247.50M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 304 people. Epizyme Inc. CEO is Robert B. Bazemore.

The one-year performance of Epizyme Inc. stock is -72.81%, while year-to-date (YTD) performance is -41.2%. EPZM stock has a five-year performance of -88.78%. Its 52-week range is between 0.41095 and 5.8341, which gives EPZM stock a 52-week price range ratio of 19.53%

Epizyme Inc. currently has a PE ratio of -0.70, a price-to-book (PB) ratio of 14.84, a price-to-sale (PS) ratio of 9.78, a price to cashflow ratio of 31.10, a PEG ratio of 2.32, a ROA of -67.89%, a ROC of -82.89% and a ROE of -828.49%. The company’s profit margin is -%, its EBITDA margin is -537.50%, and its revenue ttm is $25.48 Million , which makes it $0.15 revenue per share.

Of the last four earnings reports from Epizyme Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. Epizyme Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Epizyme Inc. is Moderate Buy (2.5), with a target price of $2.39, which is +62.59% compared to the current price. The earnings rating for Epizyme Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Epizyme Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Epizyme Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.04, ATR14 : 0.04, CCI20 : -58.82, Chaikin Money Flow : -0.27, MACD : 0.06, Money Flow Index : 10.19, ROC : -0.68, RSI : 64.52, STOCH (14,3) : 25.00, STOCH RSI : 0.00, UO : 50.25, Williams %R : -75.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Epizyme Inc. in the last 12-months were: Jeffery Kutok (Sold 2 556 shares of value $3 502 ), Jeffery L. Kutok (Sold 5 297 shares of value $5 969 ), Joseph Beaulieu (Sold 909 shares of value $1 274 ), Pablo Legorreta (Buy at a value of $34 000 000), Shefali Agarwal (Sold 9 541 shares of value $17 007 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (75.00 %)
3 (75.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Strong Buy
1.50

Epizyme Inc.

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing and commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

CEO: Robert B. Bazemore

Telephone: +1 617 229-5872

Address: 400 Technology Square, Cambridge 02139, MA, US

Number of employees: 304

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

53%47%

Bearish Bullish

47%53%

TipRanks News for EPZM

Fri, 03 Jun 2022 10:15 GMT Analysts Are Bullish on Top Healthcare Stocks: Epizyme (EPZM), Aptose Biosciences (APTO)

- TipRanks. All rights reserved.

Thu, 12 May 2022 10:26 GMT Epizyme (EPZM) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Sat, 15 Jan 2022 01:51 GMT Epizyme (EPZM) Receives a Buy from Barclays

- TipRanks. All rights reserved.

News

Stocktwits